<SEC-DOCUMENT>0001213900-21-000427-index.html : 20210105
<SEC-HEADER>0001213900-21-000427.hdr.sgml : 20210105
<ACCEPTANCE-DATETIME>20210105160118
ACCESSION NUMBER:		0001213900-21-000427
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		8
CONFORMED PERIOD OF REPORT:	20201230
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210105
DATE AS OF CHANGE:		20210105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Wize Pharma, Inc.
		CENTRAL INDEX KEY:			0001218683
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880445167
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52545
		FILM NUMBER:		21505347

	BUSINESS ADDRESS:	
		STREET 1:		24 HANAGAR ST
		CITY:			HOD HASHARON
		STATE:			L3
		ZIP:			4527713
		BUSINESS PHONE:		972 472 260 0536

	MAIL ADDRESS:	
		STREET 1:		24 HANAGAR ST
		CITY:			HOD HASHARON
		STATE:			L3
		ZIP:			4527713

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OphthaliX, Inc.
		DATE OF NAME CHANGE:	20120207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DENALI CONCRETE MANAGEMENT INC
		DATE OF NAME CHANGE:	20030213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea132523-8k_wizepharma.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
Document 1 - file: ea132523-8k_wizepharma.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>ea132523ex2-1_wizepharma.htm
<DESCRIPTION>BID IMPLEMENTATION AGREEMENT
<TEXT>
Document 2 - file: ea132523ex2-1_wizepharma.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>ea132523ex10-1_wizepharma.htm
<DESCRIPTION>FORM OF WARRANT AGENCY AGREEMENT
<TEXT>
Document 3 - file: ea132523ex10-1_wizepharma.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>ea132523ex10-2_wizepharma.htm
<DESCRIPTION>FORM OF CONTINGENT VALUE RIGHTS AGREEMENT
<TEXT>
Document 4 - file: ea132523ex10-2_wizepharma.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>5
<FILENAME>ea132523ex10-3_wizepharma.htm
<DESCRIPTION>SECURITIES PURCHASE AGREEMENT, BETWEEN WIZE PHARMA, INC. AND VARIOUS PURCHASERS, DATED DECEMBER 30, 2020
<TEXT>
Document 5 - file: ea132523ex10-3_wizepharma.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>6
<FILENAME>ea132523ex10-4_wizepharma.htm
<DESCRIPTION>SECURITIES PURCHASE AGREEMENT, BETWEEN WIZE PHARMA, INC. AND NOAM DANENBERG, DATED DECEMBER 30, 2020
<TEXT>
Document 6 - file: ea132523ex10-4_wizepharma.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>7
<FILENAME>ea132523ex99-1_wizepharma.htm
<DESCRIPTION>PRESS RELEASE, DATED JANUARY 4, 2021: WIZE PHARMA RECEIVES BONUS BIOGROUP SHARES FROM ESCROW AND ADDITIONAL BONUS BIOGROUP SHARES TOTALING $1.3 MILLION
<TEXT>
Document 7 - file: ea132523ex99-1_wizepharma.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 8 - file: ex99-1_001.jpg

</DOCUMENT>
</SEC-DOCUMENT>